Barrett Esophagus : p53
Although most cases of Barrett esophagus (BE) do not progress to adenocarcinoma, there are no well-established prognostic markers to help determine cases that will progress. Some studies have suggested that cases of BE with abnormalities in CDKN2A and TP53 may have increased risk of progression. The image shows strong immunoreactivity for p53 in BE with high-grade dysplasia. Image courtesy of: ARP Press (@ARP_Press); used with permission.